Cargando…

Different prognosis by subtype in the early mucinous breast cancer: a SEER population-based analysis

BACKGROUND: Our study aims to investigate the clinicopathological characteristics and survival outcomes of mucinous breast cancer (MBC), and explore the effect of histology type on the breast cancer-specific survival (BCSS) by different subtypes. METHODS: we identified 7,083 patients who were diagno...

Descripción completa

Detalles Bibliográficos
Autores principales: Lian, Weibin, Zheng, Juanjuan, Chen, Debo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799257/
https://www.ncbi.nlm.nih.gov/pubmed/35117209
http://dx.doi.org/10.21037/tcr-20-1237
_version_ 1784642028050579456
author Lian, Weibin
Zheng, Juanjuan
Chen, Debo
author_facet Lian, Weibin
Zheng, Juanjuan
Chen, Debo
author_sort Lian, Weibin
collection PubMed
description BACKGROUND: Our study aims to investigate the clinicopathological characteristics and survival outcomes of mucinous breast cancer (MBC), and explore the effect of histology type on the breast cancer-specific survival (BCSS) by different subtypes. METHODS: we identified 7,083 patients who were diagnosed with MBC and 248,751 with infiltrating ductal carcinoma (IDC) by using the Surveillance, Epidemiology and End Results (SEER) database. The propensity score matching was used to match baseline characteristics among MBC and IDC, and multivariable cox proportional hazards models were used to analyze the relationship between histology type stratified by subtype and BCSS. RESULTS: MBC patients were associated with a fewer nodal involvement, lower grade, earlier stage, more estrogen receptor (ER) or progesterone receptor (PR) positive, and more favorable prognosis compared to the overall IDC population. After 1:1 matching of MBC with IDC by other factors, we found that MBC patients presented better prognosis than the Matched IDC for BCSS. Analysis among ER+PR+ subgroup revealed that MBC patients was significantly better than that Matched IDC patients for BCSS (HR =0.78, 95% CI, 0.63–0.96). However, the survival analysis in the ER+PR− or ER−PR− subgroups suggested that no significant difference was seen between MBC patients and matched IDC patients for BCSS. CONCLUSIONS: Our findings support that MBC seems to be an independent factor for the better prognosis for breast cancer patients with ER+PR+ breast cancer but not in those with ER+PR− or ER−PR− disease.
format Online
Article
Text
id pubmed-8799257
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-87992572022-02-02 Different prognosis by subtype in the early mucinous breast cancer: a SEER population-based analysis Lian, Weibin Zheng, Juanjuan Chen, Debo Transl Cancer Res Original Article BACKGROUND: Our study aims to investigate the clinicopathological characteristics and survival outcomes of mucinous breast cancer (MBC), and explore the effect of histology type on the breast cancer-specific survival (BCSS) by different subtypes. METHODS: we identified 7,083 patients who were diagnosed with MBC and 248,751 with infiltrating ductal carcinoma (IDC) by using the Surveillance, Epidemiology and End Results (SEER) database. The propensity score matching was used to match baseline characteristics among MBC and IDC, and multivariable cox proportional hazards models were used to analyze the relationship between histology type stratified by subtype and BCSS. RESULTS: MBC patients were associated with a fewer nodal involvement, lower grade, earlier stage, more estrogen receptor (ER) or progesterone receptor (PR) positive, and more favorable prognosis compared to the overall IDC population. After 1:1 matching of MBC with IDC by other factors, we found that MBC patients presented better prognosis than the Matched IDC for BCSS. Analysis among ER+PR+ subgroup revealed that MBC patients was significantly better than that Matched IDC patients for BCSS (HR =0.78, 95% CI, 0.63–0.96). However, the survival analysis in the ER+PR− or ER−PR− subgroups suggested that no significant difference was seen between MBC patients and matched IDC patients for BCSS. CONCLUSIONS: Our findings support that MBC seems to be an independent factor for the better prognosis for breast cancer patients with ER+PR+ breast cancer but not in those with ER+PR− or ER−PR− disease. AME Publishing Company 2020-10 /pmc/articles/PMC8799257/ /pubmed/35117209 http://dx.doi.org/10.21037/tcr-20-1237 Text en 2020 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
spellingShingle Original Article
Lian, Weibin
Zheng, Juanjuan
Chen, Debo
Different prognosis by subtype in the early mucinous breast cancer: a SEER population-based analysis
title Different prognosis by subtype in the early mucinous breast cancer: a SEER population-based analysis
title_full Different prognosis by subtype in the early mucinous breast cancer: a SEER population-based analysis
title_fullStr Different prognosis by subtype in the early mucinous breast cancer: a SEER population-based analysis
title_full_unstemmed Different prognosis by subtype in the early mucinous breast cancer: a SEER population-based analysis
title_short Different prognosis by subtype in the early mucinous breast cancer: a SEER population-based analysis
title_sort different prognosis by subtype in the early mucinous breast cancer: a seer population-based analysis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799257/
https://www.ncbi.nlm.nih.gov/pubmed/35117209
http://dx.doi.org/10.21037/tcr-20-1237
work_keys_str_mv AT lianweibin differentprognosisbysubtypeintheearlymucinousbreastcanceraseerpopulationbasedanalysis
AT zhengjuanjuan differentprognosisbysubtypeintheearlymucinousbreastcanceraseerpopulationbasedanalysis
AT chendebo differentprognosisbysubtypeintheearlymucinousbreastcanceraseerpopulationbasedanalysis